Biling Weitong Granules in the treatment of functional dyspepsia upper abdominal pain clinical trial

Biling Weitong Granules in the treatment of functional dyspepsia upper abdominal pain multicenter phase, randomized, double-blind, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17010953

Enrollment

Unknown

Registered

2017-03-22

Start date

2017-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional dyspepsia upper abdominal pain

Interventions

Treatment Group:Biling Weitong Granules

Control Group:Placebo Granules

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Conforms to the diagnosis standard of functional dyspepsia upper abdominal pain; 2. With upper abdominal pain, VAS=4; 3. Aged 18 to 65 years old; 4. Voluntary and signed ICF.

Exclusion criteria

Exclusion criteria: 1. The hepatobiliary B ultrasound, endoscopy, laboratory examination found abnormal, dominant gastrointestinal bleeding, inflammation of the digestive tract (ulcer, erosion, bleeding, atrophy) evidence, including melena, hematemesis, palpable abdominal mass; 2. Hp positive; 3. Progressive dysphagia and swallowing pain, persistent vomiting, and unconscious weight loss; 4. A history of gastric surgery; 5. Immune function defects (such as leukemia, cancer patients, etc.), or in the past 3 months, the use of immunosuppressive agents or corticosteroids; 6. Combined with severe cardiac insufficiency, liver and kidney (detection index ALT/AST exceeded the normal value of the upper limit of 1.5 times) function, endocrine system, abnormal hematopoietic system, hematological examination showed the presence of iron deficiency anemia; 7. Patients with mental illness and mental retardation; 8. Pregnancy (pregnant women of childbearing age positive test) or lactating women; 9. Allergic to the medicine composition of the preparation; 10. In the past 3 months to participate in clinical trials; 11. Suspect or have a history of alcohol or substance abuse, or who are taking anti anxiety, anti depression, anti insomnia drugs; 12. The investigator think that is not suitable to participate in clinical trial.

Design outcomes

Primary

Measure	Time frame
Total score of upper abdominal pain symptoms;	—

Secondary

Measure	Time frame
VAS score of epigastric pain intensity;Epigastric pain frequency;Upper abdominal pain disappearance rate and disappearance time;Clinical score of functional dyspepsia;Use Hydrotalcite Tablets;	—

Countries

China

Contacts

Public ContactXudong Tang

Xi Yuan Hospital of China Academy of Chinese Medical Sciences

txdly@sina.com+86 13901137632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026